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Abstract
Objectives Invasive pulmonary aspergillosis (IPA)
caused by Aspergillus fumigatus, Aspergillus flavus, or
Aspergillus niger is associated with high mortality.
We evaluated the efficacy and compared the thera-
peutic effect differences of voriconazole (VRC) in
combination with caspofungin (CAS) in transiently
neutropenic rats infected by A. fumigatus, A. flavus, or
A. niger.
Methods Treatment groups consisted of VRC
(10 mg/kg q12 h) monotherapy, CAS (1 mg/kg/day)
monotherapy, combination of VRC (10 mg/kg
q12 h) ? CAS (1 mg/kg/day), and no drug for 10
consecutive days. The efficacy and the difference in
the treatments were evaluated through prolongation of
survival, reduction in serum galactomannan levels and
residual fungal burden, and histological studies.
Results For all the strains, the combination of VRC
and CAS led to significant prolongation in survival
(P \ 0.05) and reduction in residual fungal burden
(P \ 0.05) compared with CAS alone, and decrease in
serum galactomannan levels (P \ 0.05) compared
with either agent alone. The survival in the combined
therapy groups was significantly improved compared
to VRC monotherapy for the strains of A. flavus and A.
niger (P \ 0.05), but no significant difference for the
strains of A. fumigatus (P [ 0.05).
Conclusions Combination of VRC and CAS was
synergistic in IPA by A. flavus and A. niger, but small
efficacy benefits in IPA by A. fumigatus.
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Introduction
Invasive aspergillosis (IA) is an opportunistic infec-
tion caused by the fungi of the genus Aspergillus. Over
90 % of IA cases involve the lung, leading to invasive
pulmonary aspergillosis (IPA) [1]. Aspergillus fumig-
atus is the most common species recovered from cases
of IPA [2], followed by Aspergillus flavus and
Aspergillus niger. Liking with A. fumigatus, IPA
caused by A. flavus or A. niger is also associated with
high mortality rates [3].
Voriconazole (VRC) is considered the primary
therapy for IPA, based on the results of randomized
clinical trials [4, 5], alternatives being liposomal
amphotericin B (L-AMB), amphotericin B lipid
complex (ABLC), caspofungin (CAS), micafungin,
posaconazole, and itraconazole. Despite these treat-
ment options, the outcomes of IPA remain poor, with
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mortality rates of 25–35 % 12 weeks after diagnosis
[6]. Owing to the target of triazoles at cell membrane
and echinocandins at cell wall [4], the combination
therapy of azoles and echinocandins may result in
synergistic interaction against Aspergillus spp, includ-
ing a wider spectrum of efficacy, lowered toxicity, and
prevented the emergence of resistance [7–9]. How-
ever, some studies showed that the combination of
azole and echinocandin could not significantly
improve the therapeutic outcome [10], even may be
potentially antagonistic [11].
There are some reports of combination therapies of
azole and echinocandin in the treatment for IA
infected by A. fumigatus [7–14],more rarely by A.
flavus [15] and A. niger. In this study, we established
the model of IPA in transiently neutropenic rats
infected by A. fumigatus, A. flavus, or A. niger. The
dosage of VRC and CAS was adjusted according to the
pharmacokinetic/pharmacodynamic (PK/PD)
described in the previous studies [10, 12, 16–18].
The therapeutic efficacy and difference in both agents
in every strain, administered alone or in combination,
were examined.
Materials and Methods
Three clinical isolates of A. fumigatus, A. flavus, and
A. niger obtained from patients with proven IPA in
Jinling hospital were used in this study. The isolates
had been stored in 10 % glycerol broth at -80 C. To
prepare the inocula, the isolates were cultivated on
Sabouraud dextrose agar (SDA) at 35 C for 5 days
and cultures were then suspended in sterile 0.1 %
Triton 80 in phosphate-buffered saline (PBS) and
filtered through sterile gauze to remove hyphae. The
resulting suspensions were adjusted to the desired
concentration of 1 9 109 conidia/mL in sterile PBS by
counting with a hemacytometer. The conidial suspen-
sion was used within 24 h and stored at 4 C.
In Vitro Studies
The in vitro antifungal susceptibility test of the three
strains to VRC (Vfend, Pfizer Inc. Madrid, Spain) and
CAS (Cancidas, Merck Sharp & Dohme Pty. Ltd. New
South Wales, Australia) was performed in triplicate
according to the Clinical and Laboratory Standards
Institute (CLSI) standard M38-A2 microdilution
methods [19]. For VRC,the minimal inhibitory con-
centration (MIC) was determined, and for CAS, the
minimal effective concentration (MEC) was deter-
mined. The interactions of the combination of VRC
and CAS were evaluated by determining the fractional
concentration index (FICI) using a checkerboard
method [20]. MIC end points were determined as
MIC-0 (100 % of growth inhibition) of VRC alone and
in combination with CAS. The FICI was defined as
FICI = (Ac/Aa) ? (Bc/Ba), where Ac and Bc are the
MICs of VRC and CAS in combination, Aa is the MIC
of VRC, and Ba is the MEC of CAS, as previously
described [21–23]. Drug interactions were classified
as synergistic (FICI B 0.5), indifferent (FICI [ 0.5
but B 4), or antagonistic (FICI [ 4) [24].
Animal Model
A total of 180 male Sprague–Dawley rats, aged
6–8 weeks, weight 220–250 g, were used in these
experiments. All the animals were housed under
standard conditions and allowed ad libitum access to
food and water. This study was conducted in confor-
mity with institutional guidelines for the care and use
of laboratory animals in Jinling Hospital, Nanjing,
China, and performed according to the National
Institutes of Health Guide for Care and Use of
Laboratory Animals. Pulmonary aspergillosis was
established as described elsewhere [25]. The animals
were immunosuppressed with cyclophosphamide
(75 mg/kg of body weight intraperitoneally twice)
plus Methylprednisolone (13 mg/kg intramuscularly
once) 2 days before infection. And the animals
received Levofloxacin (Cravit; 10 mg/kg intravenous
injection daily) from day 2 preinfection to day 10 after
challenge to prevent bacterial infections. Rats were
intratracheally inoculated with a single administration
of 1 9 108 conidia of A. fumigatus, A. flavus, or A.
niger in 100 ll of sterile PBS [26].
Antifungal Treatment
The efficacy of combination therapy using VRC and
CAS was assessed in this study. For each strain and each
treatment, 180 animals were randomized into groups of
15 rats. Ten rats were assigned randomly to the survival
study and five rats for residual fungal burden and
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histopathological studies. Rats were grouped to receive
VRC 10 mg/kg q12 h intravenously, CAS 1 mg/kg/day
intravenously, a combination of VRC(10 mg/kg q12 h
intravenously)and CAS (1 mg/kg/day intravenously),
or no drug (untreated controls). All treatments began
1 day post-infection and continued for 10 days.
Survival Study
Ten rats were assigned randomly to the survival study.
The survival time after infection was recorded daily
for 15 days.
Galactomannan Assays
Blood from each rat was collected every other day to
determine serum galactomannan levels. Serum galac-
tomannan concentrations were performed by the
Platelia Aspergillus EIA (Platelia Aspergillus; Sanofi
Diagnostics, Marnes-La Coquette, France) according
to the manufacturer’s instructions. Values of EIA were
expressed as galactomannan index (GI) plotted over
time.
Residual Fungal Burden
The rats were killed on day 5 after challenge. Each
right lung, weighed individually, placed (W:V = 1:1)
in sterile 0.1 % Triton 80 in PBS, and homogenized in
a tissue homogenizer. Serial tenfold dilutions of the
homogenates were cultured for 48 h on SDA plates at
35 C. Fungal burden was expressed as log 10 CFU/g
of lung tissue.
Histopathological Study
The left lungs of the killed rats were excised and fixed
in 10 % buffered formalin. Paraffin-embedded tissue
sections were then sectioned and stained with hema-
toxylin–eosin (HE).
Statistical Analysis
Statistical evaluation of survival was done by the
Kaplan–Meier analysis. Differences in rat survival
rates were assessed by the log rank test. Galactoman-
nan serum levels and fungal burden data were assessed
by the Mann–Whitney U test. A P value of B 0.05 was
considered to be statistically significant.
Results
In Vitro Studies
The in vitro antifungal activity of VOR and CAS alone
or in combination against the three strains of Asper-
gillus is shown in Table 1. The MIC for VOR was
0.5 lg/ml for the isolate of A. fumigatus and 0.25 lg/
ml for both isolates of A. flavus and A. niger. The MEC
for CAS was 0.06 lg/ml for both isolates of A.
fumigatus and A. flavus, and 0.03 lg/ml for the isolate
of A. niger. FICI indices ranged from 0.25 to 0.50,
indicating the combination of VOR and CAS synergy
for each strain.
Survival
Survival was prolonged among the rats treated with
the combination of VRC and CAS for all the strains
(Fig. 1.). The survival of rats in the combined therapy
groups was significantly improved compared to the
CAS monotherapy for the three strains tested
(P \ 0.05), and compared to VRC alone for the
strains of A. flavus and A. niger (P \ 0.05). Even
though the survival rate of the combined therapy is
higher than the VRC monotherapy for the strain of A.
fumigatus, there were no significant differences
(P [ 0.05).
Serum Galactomannan
The serum galactomannan levels were significantly
lower in the rats combined therapy of VRC and CAS in
comparison with the other groups for all the strains
(P \ 0.05) (Fig. 2). There was no difference in VRC
groups and CAS groups in comparison with the control
Table 1 In vitro antifungal activity of voriconazole and ca-
spofungin against three strains of A. fumigatus, A. flavus, and
A. niger
Strain MIC–VRC(lg/ml) MEC–CAS(lg/ml) FICI
A. fumigatus 0.5 0.06 0.50
A. flavus 0.25 0.06 0.38
A. niger 0.25 0.03 0.25
VRC voriconazole, CAS caspofungin, MIC minimal inhibitory
concentration, MEC minimal effective concentration, FICI
fractional inhibitory concentration index
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groups (P [ 0.05). However, the levels of galacto-
mannan were significantly lower on day 6 and day 8 in
VRC groups and CAS groups compared to the control
groups (P \ 0.05).
Residual Fungal Burden
The results of the pulmonary tissue residual fungal
burden are shown in Fig. 3. There was significant
Fig. 1 Survival of rats infected with 1 9 108 conidia of
A.fumigatus (a), A. flavus (b) and A. niger (c). VRC,
voriconazole at 10 mg/kg q12-h intravenous; CAS, caspofungin
at 1 mg/kg/day intravenous. All treatments began on day 1 post-
infection and continued for 10 days. a P \ 0.05 versus
CONTROL; b P \ 0.05 versus VRC; c P \ 0.05 versus CAS
Fig. 2 Expression of
galactomannan in rats
infected by A. fumigatus (a),
A. flavus (b) and A. niger (c).
Animals treated with the
VRC and CAS combination
had significantly lower
levels of galactomannan in
comparison with all other
groups (*, P \ 0.05). VRC,
voriconazole at 10 mg/kg
q12-h intravenous; CAS,
caspofungin at 1 mg/kg/day
intravenous
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reduction of residual fungal burden (CFU/g) in the
combination of VRC- and CAS-treated rats, compared
with the effect of CAS alone, or no treatment for all the
strains (P \ 0.05). The combined therapy worked better
than VRC in only the strain of A. niger (P \ 0.05).
There were no significant differences in the combination
rats in comparison with that of VRC alone for the strain
of A. fumigatus and A. flavus (P [0.05).
Fig. 3 The mean
pulmonary tissue residual
fungal burden (log CFU/g)
in rats infected with A.
fumigatus (a), A. flavus
(b) and A. niger (c) on day 5
after challenge. VRC,
voriconazole at 10 mg/kg
q12 h intravenous; CAS,
caspofungin at 1 mg/kg/day
intravenous. a P \ 0.05
versus CONTROL;
b P \ 0.05 versus VRC; c
P \ 0.05 versus CAS
Fig. 4 The histological studies in rats infected with A.
fumigatus (a), A. flavus (b), and A. niger (c) on day 5 after
challenge. a Lung sections of control rat infected with the A.
fumigatus; HE 9 200. b Lung section of a rat infected with the
A. fumigatus treated with CAS; HE 9 200. c Lung section of a
rat infected with the A. fumigatus treated with VRC; HE 9 200.
d Lung section of a rat infected with the A. fumigatus treated
with VRC and CAS; HE 9 200
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Histopathology
The histological features of aspergillosis were studied
in the lungs of rats in all treatment groups (Fig. 4).
Histological studies of untreated control rats showed
dense clumps of hyphae and demonstrated a typical
acute angle branching septate hyphae A. fumigatus.
Rats treated with CAS showed alveolar collapse,
inflammatory infiltration, and signs of necrosis, which
were relatively mild in rats treat with VRC and the
combination of VRC and CAS.
Discussion
In this study, we investigated the efficacy of the
combination of VRC and CAS compared to both
monotherapies in vitro and in vivo using an experi-
mental model of IPA infected by A. fumigatus, A.
flavus, or A. niger. The combination of VRC and CAS
demonstrated significantly enhanced efficacy for the
strain of A. flavus and A. niger. We observed an
synergistic interaction in vitro for each strain,a
prolongation of survival,a significant reduction in
serum galactomannan levels, and residual fungal
burden (CFU/g) in combination of VRC and CAS
compared with drug alone or no treatment.
To our knowledge, this is the first study to evaluate
the therapy efficacy of the echinocandin–triazole
combination in transiently neutropenic rats infected
by A. fumigatus, A. flavus, or A. niger as measured by
the prolongation of survival, reduction pulmonary
tissue residual fungal burden, decrease in serum
galactomannan levels, and histological studies. How-
ever, the dose of VRC or CAS used and the species of
Aspergillus assayed in this study were single, which
were possible limitation of the experimental design.
For the VRC, metabolized faster in rodents than in
humans, the area under the concentration–time curve
(AUC)/MIC ratio is considered the pharmacokinetic/
pharmacodynamic (PK/PD) index determining thera-
peutic efficacy [10, 18]. For the echinocandins, such as
CAS,both the AUC/MIC and the Cmax/MIC are
considered the PK/PD index predicting efficacy [10,
12]. Van de Sande et al. [10] elucidated the pharma-
cokinetics of VOR in rats model of IPA and found that
the dosage of VRC at 10 mg/kg q12 h showed
excellent efficacy, without toxic side effects in renal
and hepatic functions. Meanwhile, several studies
showed that the dose of CAS at 1 mg/kg/d has a better
therapeutic effect in treatment IPA [12, 16, 17]. So,
there was only a single dose of VRC or CAS used in
this study. Though, as previously described [7, 10, 11,
13], we used one sensitive isolate of each of the
species of Aspergillus assayed, this may be a limita-
tion of the study.
There are contradictory results in the previous
studies VRC combined echinocandin treatment for
invasive aspergillosis (IA). Van de Sande et al. [10], in
a neutropenic rat model of IPA by A. fumigatus, found
combining of VRC and anidulafungin (AFG) does not
significantly prolong the survival compared to the
VOR monotherapy(P = 0.3290). Petraitis et al. [13]
demonstrated that the survival of persistently neutro-
penic rabbits of IPA by A. fumigatus treatment with
VRC (10 mg/kg every 8 h) combined with AFG at
5 mg/kg/day was 60 %, but 27 % for the
VRC ? AFG (10 mg/kg/day) group (P \ 0.001). It
suggested that AFG at a dosage of 5 mg/kg/day was
synergistic but antagonistic at 10 mg/kg/day. In our
study, combining both agents worked better than CAS
alone in each strains and better than VRC in the strains
of A. flavus and A. niger. Similarly, the therapy with
VRC and CAS combined in guinea pig models of IA
by A. fumigatus significantly improved survival and
achieved significant reduction in residual fungal
burden compared to respective monotherapies [16].
In other studies [15], the combined treatment of VRC
and AFG in a murine IA model infected by A. flavus
was found to significantly improve the survival,
reduce the fungal burden and the galactomannan
levels in comparison with AFG alone, but significantly
improved only in a few cases compared to VRC alone.
In the in vitro studies, our results showed each
Aspergillus was susceptible for VRC and AFG and
synergistic effect of VRC combined with AFG.
Seyedmousavi et al. [23], in a non-neutropenic murine
model of IA by VRC-susceptible or VRC-resistant A.
fumigatus, demonstrated that the combination of VRC
and AFG was synergistic in VRC-susceptible IA, but
additive in VRC-resistant IA. Comparison with the
previous studies, there are certain discrepancies.
These might be due to the deviation of the type and
number of animals, infection route and dose, thera-
peutic dosage, and so on.
Our results demonstrated VRC monotherapy is more
therapeutically effective than the use of CAS in the rats
of IPA by A. fumigatus. Combination of VRC and CAS
16 Mycopathologia (2014) 177:11–18
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does not significantly improve the survival in the
treatment for experimental IPA by A. fumigatus. While
in the rats of IPA by A. flavus or A. niger, our data
confirm the therapy of VRC and CAS significantly
improve the therapeutic outcome compared with drug
alone. It suggests that the efficacy of the combination is
different between Aspergillus species and the efficacy
in A. flavus and A. niger is better than in A. fumigatus.
However, there are some studies of combination
therapy for IPA by A. fumigatus [7, 10, 12–14], more
rarely by A. flavus [15, 27] and A. niger [27, 28]. The
therapeutic outcome of the studies or cases of IPA by A.
flavus or A. niger are generally successful.
In conclusion, there is a synergistic effect of the
combination of VRC and CAS in the treatment for IPA
by A. flavus and A. niger. Meanwhile, our data indicate
that the echinocandin–triazole combination in com-
parison with single agents may confer a small efficacy
benefits in the treatment for IPA by A. fumigatus. The
efficacy of the echinocandin–triazole combination for
IPA by A. fumigatus, A. flavus, and A. niger needs
further clinical studies.
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